Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-03-13
2007-03-13
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S141100, C424S143100, C424S155100, C424S181100, C435S007230, C435S069600, C435S070210, C530S387300, C530S388100, C530S388220, C530S388850, C530S391300, C530S391700
Reexamination Certificate
active
10647818
ABSTRACT:
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.
REFERENCES:
patent: 4861581 (1989-08-01), Epstein
patent: 5171665 (1992-12-01), Hellstrom
patent: 5484596 (1996-01-01), Hanna
patent: 5616468 (1997-04-01), Salmi
patent: 5693763 (1997-12-01), Codington
patent: 5750102 (1998-05-01), Eisenbach
patent: 5780033 (1998-07-01), Torchilin
patent: 5783186 (1998-07-01), Arakawa
patent: 5849876 (1998-12-01), Linsley
patent: 5869045 (1999-02-01), Hellstrom
patent: 5869268 (1999-02-01), Kudo
patent: 5879898 (1999-03-01), Tarin
patent: 5885575 (1999-03-01), Herrlich
patent: 5916561 (1999-06-01), Adolf
patent: 5942417 (1999-08-01), Ni
patent: 6657048 (2003-12-01), Young et al.
patent: 2003/0103985 (2003-06-01), Adolf
patent: 2004/0001789 (2004-01-01), Young et al.
patent: 2004/0101530 (2004-05-01), Young et al.
patent: 2004/0105815 (2004-06-01), Young et al.
patent: WO 9412631 (1994-06-01), None
patent: WO02/094879 (2002-11-01), None
Campbell et al. Biology, 5th ed. p. 856, 1999.
M. Allouche et al, “Ligation of the CD44 Adhesion Molecule Inhibits Drug-Induced Apoptosis in Human Myelold Leukemia Cells”, Blood, 96(3):1187-1190 (Aug. 2000).
I. Barshack et al, “CD44 Expression in Normal Adrenal Tissue and Adrenal Tumors”, J. Clin. Pathol., 51:52-54 (1998).
R. Breyer et al, “Disruption of Intracerebral Progression of C6 Rat Glioblastoma by in vivo Treatment with Anti-CD44 Monoclonal Antibody”, J. Neurosurg., 92:140-149 (Jan. 2000).
D. Colnot et al, “Reinfusion of Unprocessed, Granulocyte Colony-Stimulating Factor-Stimulated Whole Blood Allows Dose Escalation of 186Relabeled Chimeric Monoclonal Antibody U36 Radioimmunotherapy in a Phase I Dose Escalation Study”, Clin. Cancer Res., 8:3401-3406 (Nov. 2002).
D. Colnot et al, “Radioimmunotherapy in Patients with Head and Neck Squamous Cells Carcinoma:Initial Experience”, Head & Neck, 23:559-565 (Jul. 2001).
D. Colnot et al, “Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck”, J. Nucl. Med., 41:1999-2010 (Dec. 2000).
D. Colnot et al, “Evaluation of Limited Blood Sampling in a Preceding 99m TC-Labeled Diagnostic Study to Predict the Pharmacokinetics and Myelotoxicity of 186Re-cMAB U36 Radioimmunotherapy”, J. Nucl. Med., 42(9):1364-1367 (Sep. 2001).
A. Daar et al, “The Membrane Antigens of Human Colorectal Cancer Cells:Demonstration with Monoclonal Antibodies of Heterogeneity within and between Tumours and of Anomalous Expression of HLA-DR”, Eur. J. Cancer Clin. Oncol., 19(2):209-220 (1983).
R. De Bree et al, “Selection of Monoclonal Antibody E48 IgG or U36 IgG for Adjuvant Radioimmunotherapy in Head and Neck Cancer Patients”, British J. Cancer, 75(7):1049-1060 (1997).
R. De Bree et al, “Radioimmunoscintigraphy and Biodistribution of Technetium-99m-labeled Monoclonal Antibody U36 in Patients with Head and Neck Cancer”, Clin. Can. Res., 1:591-598 (Jun. 1995).
S. Denning et al, “Antibodies Against the CD44 p80, Lymphocyte Homing Receptor Molecule Augment Human Peripheral Blood T Cell Activation”, J. Immunol., 144:7-15 (Jan. 1990).
B. Flanagan et al, “Chemical Composition adn Tissue Distribution of the Human CDw44 Glycoprotein”, Immunol., 67:167-175 (1989).
S. Fox et al, “Normal Human Tissues, in Addition to Some Tumors, Express Multple Different CD44 Isoforms”, Cancer Res., 54:4539-4546 (Aug. 1994).
U. Gunthert et al, “A New Variant of Glycoprotein CD44 Confers Metastatic Potential to Rat Carcinoma Cells”, Cell, 65:13-24 (Apr. 1991).
Y. Guo et al, “Inhibition of Human Melanoma Growth and Metastasis in vivo by Anti-CD44 Monoclonal Antibody”, Cancer Res., 54:1561-1565 (Mar. 1994).
K. Heider et al, “Differential Expression of CD44 Splice Variants in Intestinal- and Diffuse-Type Human Gastric Carcinomas and Normal Gastric Mucosa”, Cancer Res., 53:4197-4203 (Sep. 1993).
K. Heider et al, “A Human Homologue of the Rat Metastasis-associated Variant of CD44 is Expressed in Colorectal Carcinomas and Adenomatous Polyps”, J. Cell Biol., 120:227-233 (Jan. 1993).
K. Heider et al, “Splice Variants of the Cell Surface Glycoprotein CD44 Associated with Metastatic Tumour Cells are Expressed in Normal Tissues of Humans and Cynomolgus Monkeys”, Eur. J. Cancer, 31A(13/14):2385-2391 (1995).
K. Heider et al, “Characterization of a High-Affinity Monoclonal Antibody Specific for CD44v6 as Candidate for Immunotherapy of Squamous Cell Carcinomas”, Cancer Immunol. Immunother., 43:245-253 (1996).
S. Jalkanen et al, “Biochemical Properties of Glycoproteins Involved in Lymphocyte Recognition of High Endothelial Venules in Man”, J. Immunol., 141:1615-1623 (Sep. 1988).
S. Kayastha et al, “Expression of the Hyaluronan Receptor, CD44S, in Epithelial Ovarian Cancer is an Independent Predictor of Survival”, Clin. Cancer Res., 5:1073-1076 (May 1999).
S. Kennel et al, “CD44 Expression on Murine Tissues”, J. Cell Science, 104:373-382 (1993).
M. Khoursheed et al, “Expression of CD44s in Human Colorectal Cancer”, Pathology Oncology Research, 8(3):170-174 (2002).
G. Koopman et al, “Activated Human Lymphocytes and Aggressive Non-Hodgkin's Lymphomas Express a Homologue of the Rat Metastasis-associated Variant of CD44”, J. Exp. Med., 177:897-904 (Apr. 1993).
M. Kuppner et al, “Differential Expression of the CD44 Molecule in Human Brain Tumours”, Int. J. Cancer, 50:572-577 (1992).
C. Mackay et al, “Expression and Modulation of CD44 Variant Isoforms in Humans”, J. Cell Biol., 124:71-82 (Jan. 1994).
D. Naor et al, “CD44 in Cancer”, Critical Reviews in Clinical Laboratory Science, 39(6):527-579 (2002).
H. Ponta et al, “CD44: from Adhesion Molecules to Signalling Regulators”, Nature Reviews, Molecular Cell Biology, 4:33-45 (Jan. 2003).
J. Ross et al, “Expression of the CD44 Cell Adhesion Molecule in Urinary Bladder Transitional Cell Carcinoma”, Mod. Pathol., 9(8):854-860 (1996).
M. Sami et al, “Regulated Expression of Exon v6 Containing Isoforms of CD44 in Man: Downregulation During Malignant Transformation of Tumors of Squamocellular Origin”, J. Cell Biol., 122(2):431-442 (Jul. 1993).
A. Schrijvers et al, “MAb U36, a Novel Monoclonal Antibody Successful in Immunotargeting of Squamous Cell Carcinoma of the Head and Neck”, Cancer Res., 53:4383-4390 (Sep. 1993).
S. Seiter et al, “Prevention of Tumor Metastasis Formation by Anti-Variant CD44”, J. Exp. Med., 177:443-455 (Feb. 1993).
Y. Shimizu et al, “Dual Role of the CD44 Molecule in T Cell Adhesion and Activation”, J. Immunol., 143:2457-2463 (Oct. 1989).
T. Strobel et al, “In Vivo Inhibition of CD44 Limits Intra-Abdominal Spread of a Human Ovarian Cancer Xenograft in Nude Mice:A Novel Role for CD44 in the Process of Peritoneal Implantation”, Cancer Res., 57:1228-1232 (Apr. 1997).
J. Stroomer et al, “Safety and Biodistribution of 99m Technetium-labeled Anti-CD44v6 Monoclonal Antibody BIWA 1 in Head and Neck Cancer Patients”, Clin. Can. Res., 6:3046-3055 (Aug. 2000).
N. Van Hal et al, “Monoclonal Antibody U36, a Suitable Candidate for Clinical Immunotherapy of Squamous-Cell Carcinoma, Recognizes a CD44 Isoform”, Int. J. Cancer, 68:520-527 (1996).
S. Wallach-Dayan et al, “CD44-Dependent Lymphoma Cell Dissemination:a Cell Surface CD44 Variant, Rather than Standard CD44, Supports in vitro Lym
Findlay Helen P.
Hahn Susan E.
Young David S. F.
Arius Research Inc.
Blanchard David J.
Huff Sheela J.
McHale & Slavin P.A.
LandOfFree
Cytotoxicity mediation of cells evidencing surface... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxicity mediation of cells evidencing surface..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxicity mediation of cells evidencing surface... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3761455